- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04290156
The Effect of Joint Transition Visits on Quality of Life in Inflammatory Bowel Diseases (TRANS-IBD) (TRANS-IBD)
The Effect of Joint Transition Visits on Quality of Life in Adolescents With Inflammatory Bowel Diseases: a Protocol for a Prospective, Randomized, Multicentre, Controlled Trial (TRANS-IBD)
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Adrienn Erős, MD
- Telefonnummer: +36703794131
- E-Mail: adriennhat@gmail.com
Studieren Sie die Kontaktsicherung
- Name: Patrícia Sarlós, MD, PhD
- Telefonnummer: +3672536000
- E-Mail: sarlos.patricia@pte.hu
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- established IBD diagnosis based on the modified "Porto Criteria" at least 6 months prior to enrolment (date of the diagnostic endoscopy)
- any form of IBD (including Crohn's disease or ulcerative colitis) regardless of disease activity and treatment
- patient aged between 16.75 and 17 years at allocation
- at least one visit attendance at the pediatric gastroenterologist in the year prior to enrolment (aiming to minimize non-adherence with the intervention)
- signed written informed consent from the legal guardian and informed assent from the patients
Exclusion Criteria:
- diagnosis of unclassified IBD (IBD-U)
- pregnancy
- medically certified developmental or intellectual disabilities (when it is expected that the patient is unable to fill the questionnaires)
- history of cancer or active cancer treatment
- BMI ≥ 40
- concomitant participation in another interventional clinical trial
- conditions when follow-up cannot be fulfilled (e.g., plan for studying or working abroad after the age of 18)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Versorgungsforschung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Joint visits
Subjects in the intervention arm attend a total of four joint transition visits performed with the participation of both the adult and the pediatric gastroenterologist.
|
The intervention is the implementation of joint transition visits with the participation of both the pediatric and the adult gastroenterologist.
One-year intervention period was chosen.
In total, there are four joint visits every third months for the adolescents aged 17-18.
Each joint visit lasts for at least for 20 minutes, although in case of complex medical history, there is no restriction with respect to the length of the visit.
Joint transition visits 1, 2 and 3 (V1-3) are led by the pediatric gastroenterologist, and visit 4 (V4) is led by the adult gastroenterologist.
|
Kein Eingriff: Usual care
Adolescents meet only the pediatric gastroenterologist, but there is a balanced consultation between the two gastroenterologists with respect the patient's treatment plan.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Change in patient reported health-related quality of life (HRQoL) one year after transfer
Zeitfenster: 24 months
|
HRQoL is measured with a validated and IBD-specific questionnaire, called IMPACT III (HR) (unabbreviated scale title is not existing).
It consists of 35-items, using a five-point Likert self-completed response scale.
The questions are related to the severity and frequency of the following symptoms over the last two weeks: bowel symptoms, systemic symptoms, emotional functioning, social functioning, body image and treatments or interventions.
The lowest score is 35, that can be achieved, and the maximum is 175 points.
Higher scores indicate better HRQoL.
|
24 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
The number of patients not lost to follow-up
Zeitfenster: 24 months
|
Patients are considered as not lost to follow-up if they attend at least three out of the five planned visits with the adult gastroenterologist (AGE) during the follow-up period.
Previously cancelled and then rescheduled AGE visits are acceptable.
|
24 months
|
Medication adherence
Zeitfenster: 24 months
|
Measured with the Medical Adherence Report Scale (MARS-5) which consist of five statements with respect to the patient's medical adherence in the last one week.
Patients can describe their behavior on a five-point Likert response scale ranging from 'always' to 'never' (1-5 points).
The lowest total score that can be achieved is 5 (lowest adherence), while the highest is 25 (maximal adherence).
Higher scores indicate better medical adherence.
|
24 months
|
Self-efficacy: IBDSES-A
Zeitfenster: 24 months
|
Measured with IBD Self-Efficacy Scale for adolescents and young adults (IBDSES-A) questionnaire, which investigates the person's confidence in their ability to manage demands and is predictive of health outcomes in chronic disease.
The maximum scores range from 21 to 57 (as reverse scoring is used in case of 2 items).
Higher scores indicate higher self-efficacy.
|
24 months
|
Patient's satisfaction: CACHE
Zeitfenster: 24 months
|
Measured with CACHE questionnaire (unabbreviated scale title is not existing), which consists of 31 questions with respect to the attitude of the medical team, the location, accessibility, and facilities of the IBD centre.
Questions can be answered with a five-point Likert response scale.
The final score can be given on a scale that ranges from 0 (minimum satisfaction) to 100 (maximum satisfaction).
The final total score is calculated with standardization, using the following formula to determine the points of each individual item: (real score-minimum score)/ (maximum score-minimum score) ×100.
Higher score indicates higher level of satisfaction.
|
24 months
|
Transition readiness (1)
Zeitfenster: 24 months
|
Transition readiness is measured with the validated tool of Transition Readiness Questionnaire (STARx).
STARx consists of three modules (with a total of 18 items), aiming to investigate the sense of responsibility, the disease-specific knowledge and the independency of the patients.
Each item can be answered using a five-point Likert response scale and can be scored between 1 and 5 points.
The maximum score is 90, higher score indicates better transition readiness.
STARx is filled out by the participating adolescents and by their legal guardian too.
|
24 months
|
Transition readiness (2)
Zeitfenster: 24 months
|
Transition readiness is measured with the validated tool of Transition Readiness Assessment Questionnaire (TRAQ).
TRAQ consisting of 20 items and assesses the adolescents' willingness to be involved in or to be completely independent in managing disease related tasks (e.g., taking medications, making appointments, getting medications prescribed).
A five-point Likert response scale (with scores range from 1 to 5) is used for answering each question.
A total of 100 point can be acquired.
In case of both tool, higher total scores indicate a higher level of transition readiness.
|
24 months
|
The number of flare-ups
Zeitfenster: 24 months
|
Flare-ups are defined as clinical symptoms suggesting disease activity, accompanied with biochemical (e.g., stool calprotectin, c-reactive protein (CRP)), endoscopic, or imaging evidence of inflammation.
Intensifying disease symptoms resulting in dose escalation or initiation of a new drug aiming to achieve remission are also considered as flare-ups.
|
24 months
|
The number of patients who needed the initiation of corticosteroid treatment
Zeitfenster: 24 months
|
The number of patients who needed the initiation of corticosteroid treatment including the initiation of topical and systemic steroid formulations
|
24 months
|
The number of patients who needed the initiation of biological treatment
Zeitfenster: 24 months
|
The number of patients who needed the initiation of biological treatment including the initiation of all types of biologics registered for the treatment of IBD
|
24 months
|
Stool calprotectin level
Zeitfenster: 24 months
|
Measured in unit: mg/g
|
24 months
|
Disease activity (1)
Zeitfenster: 24 months
|
In case of Crohn's disease, Pediatric Crohn's Disease Activity Index (PCDAI) is being used for the assessment of disease activity. PCDAI counts with clinical symptoms (e. g. abdominal pain, stool frequency) and laboratory parameters (e.g.: haematocrit, erythrocyte sedimentation rate, serum albumin level). The minimum of 0 point can be achieved, while the maximum is 110 points. Higher score indicates higher disease activity. (<10 points: Remission; 11-30 points: Moderate disease activity; >31 points: Severe disease activity) |
24 months
|
Disease activity (2)
Zeitfenster: 24 months
|
In case of Ulcerative Colitis, Pediatric Ulcerative Colitis Activity Index (PUCAI) is being used for the assessment of disease activity. PUCAI counts with clinical symptoms (e.g. abdominal pain, rectal bleeding, and activity level). The minimum of 0 point can be achieved, while the maximum is 85 points. Higher score indicates higher disease activity. (<10 points: Remission; 11-30 points: Moderate disease activity; >31 points: Severe disease activity) |
24 months
|
Disease activity (3)
Zeitfenster: 24 months
|
In case of luminal Crohn's disease, Crohn's Disease Activity Index (CDAI) is being used for the assessment of disease activity. CDAI is the sum of eight components (clinical symptoms (e.g. abdominal pain, number of liquid stools), finding of the physical examination (e.g. abdominal mass, body weight), laboratory parameters (e.g. Haematocrit)) to each of which is assigned a specific weight. The minimum of 0 point can be achieved, while the maximum is 600 points. Higher score indicates higher disease activity. (<150 points: Inactive disease; 151-220 points: Mild disease activity; 221-300: Moderate disease activity; 301-450: Severe disease activity; >450: Fulminant disease activity) |
24 months
|
Disease activity (4)
Zeitfenster: 24 months
|
In case of perianal Crohn's disease perianal Crohn's Disease Activity Index (pCDAI) is being used for the assessment of disease activity. pCDAI counts with the discharge, the pain/ restrictions of activities, the restrictions of sexual activities, and with the type of perianal disease. The minimum of 0 point can be achieved, while the maximum is 20 points. Higher score indicates higher perianal disease activity. |
24 months
|
Disease activity (5)
Zeitfenster: 24 months
|
In case of Ulcerative Colitis Mayo score is being used for the assessment of disease activity. Mayo score clinical symptoms (e.g. abdominal pain, rectal bleeding), findings of the endoscopy, and the physician's global assessment). The minimum of 0 point can be achieved, while the maximum is 12 points. Higher score indicates higher disease activity. (0-3 points: inactive disease, 4-6 points: mild disease activity, 7-9 points: moderate disease activity, >9 points: severe disease activity) |
24 months
|
Laboratory parameter refers to inflammation: C-reactive protein (CRP)
Zeitfenster: 24 months
|
C-reactive protein (CRP) is measured in unit: mg/l.
Higher value of CRP indicates greater inflammation.
|
24 months
|
Laboratory parameter refers to inflammation: White blood cell count (WBC)
Zeitfenster: 24 months
|
White blood cell count (WBC) is measured in unit: G/L.
Higher value of WBC indicates greater inflammation.
|
24 months
|
Laboratory parameter refers to inflammation: Erythrocyte sedimentation rate (ESR)
Zeitfenster: 24 months
|
Erythrocyte sedimentation rate (ESR) is measured in unit: mm/hour.
Higher value of ESR indicates greater inflammation.
|
24 months
|
The number of unplanned visits at the caregiver gastroenterologist
Zeitfenster: 24 months
|
Medical visits, which were not arranged in advance with the caring gastroenterologist, are considered unplanned visits
|
24 months
|
The number of visits at the emergency department
Zeitfenster: 24 months
|
The number of visits at the emergency department, which are needed due to acute severe symptoms of IBD
|
24 months
|
The number of scheduled imaging performed
Zeitfenster: 24 months
|
The number of images including abdominal ultrasound, x-ray, MRI, CT-scan and other images, which were arranged in advance
|
24 months
|
The number of urgent imaging performed
Zeitfenster: 24 months
|
The number of images including abdominal ultrasound, x-ray, MRI, CT-scan and other images, which were not arranged in advance
|
24 months
|
The number of scheduled endoscopies performed
Zeitfenster: 24 months
|
The number of endoscopies including gastroduodenoscopy and colonoscopy, which were arranged in advance
|
24 months
|
The number of urgent endoscopies performed
Zeitfenster: 24 months
|
The number of endoscopies including gastroduodenoscopy and colonoscopy, which were not arranged in advance
|
24 months
|
The number of IBD-related surgical interventions performed
Zeitfenster: 24 months
|
The number of surgical interventions, which were performed because of IBD
|
24 months
|
The number of IBD related hospital admissions
Zeitfenster: 24 months
|
The number of hospital admissions, which were needed because of IBD
|
24 months
|
The length of IBD-related hospitalization
Zeitfenster: 24 months
|
The length of the IBD-related hospitalization given in days.
|
24 months
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Patrícia Sarlós, MD, PhD, First Department of Medicine, University of Pécs, Medical School, Pécs, Hungary
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Brooks AJ, Smith PJ, Cohen R, Collins P, Douds A, Forbes V, Gaya DR, Johnston BT, McKiernan PJ, Murray CD, Sebastian S, Smith M, Whitley L, Williams L, Russell RK, McCartney SA, Lindsay JO. UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care. Gut. 2017 Jun;66(6):988-1000. doi: 10.1136/gutjnl-2016-313000. Epub 2017 Feb 21.
- van Rheenen PF, Aloi M, Biron IA, Carlsen K, Cooney R, Cucchiara S, Cullen G, Escher JC, Kierkus J, Lindsay JO, Roma E, Russell RK, Sieczkowska-Golub J, Harbord M. European Crohn's and Colitis Organisation Topical Review on Transitional Care in Inflammatory Bowel Disease. J Crohns Colitis. 2017 Sep 1;11(9):1032-1038. doi: 10.1093/ecco-jcc/jjx010.
- Suris JC, Akre C. Key elements for, and indicators of, a successful transition: an international Delphi study. J Adolesc Health. 2015 Jun;56(6):612-8. doi: 10.1016/j.jadohealth.2015.02.007.
- Fair C, Cuttance J, Sharma N, Maslow G, Wiener L, Betz C, Porter J, McLaughlin S, Gilleland-Marchak J, Renwick A, Naranjo D, Jan S, Javalkar K, Ferris M; International and Interdisciplinary Health Care Transition Research Consortium. International and Interdisciplinary Identification of Health Care Transition Outcomes. JAMA Pediatr. 2016 Mar;170(3):205-11. doi: 10.1001/jamapediatrics.2015.3168.
- van den Brink G, van Gaalen MAC, de Ridder L, van der Woude CJ, Escher JC. Health Care Transition Outcomes in Inflammatory Bowel Disease: A Multinational Delphi Study. J Crohns Colitis. 2019 Sep 19;13(9):1163-1172. doi: 10.1093/ecco-jcc/jjz044.
- Eros A, Soos A, Hegyi P, Szakacs Z, Eross B, Parniczky A, Mezosi E, Rumbus Z, Sarlos P. Spotlight on Transition in Patients With Inflammatory Bowel Disease: A Systematic Review. Inflamm Bowel Dis. 2020 Feb 11;26(3):331-346. doi: 10.1093/ibd/izz173.
- Eros A, Dohos D, Veres G, Tarnok A, Vincze A, Teszas A, Zadori N, Gede N, Hegyi P, Sarlos P. Effect of joint transition visits on quality of life in adolescents with inflammatory bowel diseases: a protocol for a prospective, randomised, multicentre, controlled trial (TRANS-IBD). BMJ Open. 2020 Oct 6;10(10):e038410. doi: 10.1136/bmjopen-2020-038410.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Voraussichtlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 50457-2/2019/EKU
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Entzündliche Darmerkrankungen
-
Arkansas Children's Hospital Research InstituteEunice Kennedy Shriver National Institute of Child Health and Human Development...BeendetSIRS (Systemic Inflammatory Response Syndrome)Vereinigte Staaten
-
University of ArkansasBeendetPädiatrische Patienten mit SIRS (Systemic Inflammatory Response Syndrome)Vereinigte Staaten
Klinische Studien zur joint visits
-
Ensol BioscienceAbgeschlossen
-
Wuerzburg University Hospitalaycan Medical Systems LTD, Innere Aumuehlstr. 5, 97076 Wuerzburg , GermanyAktiv, nicht rekrutierendFettleibigkeit | Kandidat für bariatrische ChirurgieDeutschland
-
Kessler FoundationChildren's Specialized HospitalRekrutierungHemiplegische ZerebralpareseVereinigte Staaten
-
National Bureau of Economic Research, Inc.Emory UniversityAbgeschlossenErworbenes Immunschwächesyndrom | HIVVereinigte Staaten
-
Swedish Orphan BiovitrumKantar Health; Cerner Enviza (former Kantar Health)AbgeschlossenHämophilie A | Hämophilie BFrankreich
-
The University of Texas Health Science Center,...National Cancer Institute (NCI); Fox Chase Cancer Center; University of Kansas; New... und andere MitarbeiterNoch keine RekrutierungKopf-Hals-KrebsVereinigte Staaten
-
Joint AcademyLund UniversitySuspendiertSchmerzen | Arthrose, Knie | Arthrose, Hüfte | Gesundheitsbezogene Lebensqualität | FunktionSchweden
-
Joint AcademyLund UniversityAbgeschlossenSchmerzen | Physische FunktionSchweden
-
Dana-Farber Cancer InstituteAbgeschlossenBrustkrebs | Prostatakrebs | Patientenbindung | Patientenzufriedenheit | PatientenpräferenzVereinigte Staaten
-
Joint AcademyLund UniversityAbgeschlossenSchulterschmerzen | Subakromiales SchmerzsyndromSchweden